Akero Therapeutics to Present at the Jefferies London Healthcare Conference

AKRO 11.13.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Jefferies London Healthcare Conference
Full Press ReleaseSEC FilingsOur AKRO Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
  • 01.07.2025 - Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.02.2025 - 144 Report of proposed sale of securities
PDF Version

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website atwww.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero TherapeuticsAkero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONYHistology, SYNCHRONYReal-World, and SYNCHRONYOutcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us atakerotx.comand follow us onLinkedInandXfor more information.

Investor Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com

Media Contact:Peg Rusconi617.910.6217peg.rusconi@deerfieldgroup.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com